Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

49 results about "Pim kinases" patented technology

Pim kinases are constitutively active serine/threonine kinases that promote growth factor-independent proliferation by phosphorylating, and thus inhibiting, a range of cellular proteins. They are serine/threonine kinases that control cell growth, differentiation and apoptosis.

Methods for inhibiting protein kinases

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.
Owner:SCHERING CORP

Protein kinase modulators

The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and / or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
Owner:SENHWA BIOSCIENCES INC

IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS

ActiveUS20080261988A1Inhibits protein kinase activityInhibitory activityBiocideOrganic chemistryPTK InhibitorsPim kinases
The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II):or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.
Owner:SUMITOMO PHARMA ONCOLOGY INC

Protein kinase modulators

InactiveUS20120208792A1BiocideNervous disorderFms-Like Tyrosine KinasePolymerase L
The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and / or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
Owner:SENHWA BIOSCIENCES INC

Pyridine derivatives as pim kinase inhibitors and preparation methods and use in medicinal manufacture thereof

ActiveUS20150284363A1Promote apoptosisModulating protein kinase activityBiocideOrganic chemistryDiseaseEnantiomer
PIM kinase inhibitor compound having a structure as represented by Formula I, and isomers, diastereomers, enantiomers, tautomers, and pharmaceutically acceptable salts thereof. The compounds significantly inhibit the Pim kinase activity and are used to prepare drugs to treat PIM kinase mediated diseases, such as cancers, multi drug resistance, and inflammatory bowel disease. Also provided are methods for preparing and using the compounds represented by Formula I.
Owner:JIKAI BIOSCI

Pim kinase inhibitor combinations

InactiveUS20160175293A1Significant inhibitory activityGood pharmacological propertiesBiocideHeavy metal active ingredientsOncologyMyeloid Neoplasm
The present invention relates to a Pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a JAK inhibitor compound, (b) a Pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.
Owner:NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products